|Bid||8,309.00 x 0|
|Ask||8,314.00 x 0|
|Day's range||8,151.00 - 8,334.00|
|52-week range||6,499.80 - 9,523.00|
|Beta (5Y monthly)||0.15|
|PE ratio (TTM)||101.92|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||2.02 (2.42%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||98.42|
WILMINGTON, Del., November 30, 2021--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.
Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. Shares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the S&P 500 has soared by more than 5%. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine.
Stifel Chief Equity Strategist Barry Bannister joins Yahoo Finance Live to discuss the investor implications of a newly discovered COVID-19 variant as we enter the second winter of the pandemic.